Document is current
Any future updates will be listed below
-
Authors
Singh, N N
Howell, M D
Androphy, E J
Singh, R N
- License Information
-
More Information
Article History
Received: 19 February 2017
Revised: 14 April 2017
Accepted: 26 April 2017
First Online: 9 May 2017
Competing interests
: The ISS-N1 target (US7838657) was discovered in the Singh laboratory at UMass Medical School (MA, USA). Inventors, including RNS, NNS, EJA and UMASS Medical School, are currently benefiting from licensing of the ISS-N1 target to Ionis Pharmaceuticals. Iowa State University holds intellectual property rights on GC-rich sequence (GCRS) and ISS-N2 targets. Therefore, inventors including RNS, NNS and Iowa State University could potentially benefit from any future commercial exploitation of GCRS and ISS-N2 targets. MDH has no conflict of interest to declare.
